OBJECTIVE: To test the efficacy of locally produced Vi vaccine over a time period of longer than one year. METHODS: A double-blinded, randomized field trial was performed in Guangxi Zhuang Autonomous Region in south-western China, using 30 micrograms doses of locally produced Vi. Enrolled subjects were 3-50 years of age, although the majority (92%) were school-aged children, who have the highest rate of typhoid fever in this setting. A total of 131,271 people were systematically allocated a single dose of 30 micrograms of Vi polysaccharide or saline placebo. The study population was followed for 19 months, with passive surveillance conducted in the Ministry of Health and the Regional Health and Anti-epidemic Centre (HAEC). Clinically suspected cases of typhoid fever were confirmed by blood culture, or by serological reaction with O-antigen (Widal tests). FINDINGS: After 19 months, there were 23 culture-confirmed cases of typhoid fever in the placebo group versus 7 cases in the Vi group (Protective efficacy (PE) = 69%; 95% CI = 28%, 87%). Most of the isolates were from school-aged children: 22 cases in the placebo group versus 6 in the Vi group (PE = 72%; 95% CI = 32%, 82%). No serious post-injection reactions were observed. The locally produced Vi polysaccharide vaccine showed levels of protective efficacy similar to those for Vi vaccine produced in industrial countries. CONCLUSION: The slightly higher dose of vaccine did not seem to alter efficacy significantly in China.
RCT Entities:
OBJECTIVE: To test the efficacy of locally produced Vi vaccine over a time period of longer than one year. METHODS: A double-blinded, randomized field trial was performed in Guangxi Zhuang Autonomous Region in south-western China, using 30 micrograms doses of locally produced Vi. Enrolled subjects were 3-50 years of age, although the majority (92%) were school-aged children, who have the highest rate of typhoid fever in this setting. A total of 131,271 people were systematically allocated a single dose of 30 micrograms of Vi polysaccharide or saline placebo. The study population was followed for 19 months, with passive surveillance conducted in the Ministry of Health and the Regional Health and Anti-epidemic Centre (HAEC). Clinically suspected cases of typhoid fever were confirmed by blood culture, or by serological reaction with O-antigen (Widal tests). FINDINGS: After 19 months, there were 23 culture-confirmed cases of typhoid fever in the placebo group versus 7 cases in the Vi group (Protective efficacy (PE) = 69%; 95% CI = 28%, 87%). Most of the isolates were from school-aged children: 22 cases in the placebo group versus 6 in the Vi group (PE = 72%; 95% CI = 32%, 82%). No serious post-injection reactions were observed. The locally produced Vi polysaccharide vaccine showed levels of protective efficacy similar to those for Vi vaccine produced in industrial countries. CONCLUSION: The slightly higher dose of vaccine did not seem to alter efficacy significantly in China.
Authors: B Dong; C M Galindo; E Shin; C J Acosta; A L Page; M Wang; D Kim; R L Ochiai; J Park; M Ali; L V Seidlein; Z Xu; J Yang; J D Clemens Journal: Epidemiol Infect Date: 2007-01-12 Impact factor: 2.451
Authors: Tanner M Johanns; Calvin Y Law; Lokeshchandra A Kalekar; Hope O'Donnell; James M Ertelt; Jared H Rowe; Sing Sing Way Journal: Microbes Infect Date: 2010-12-04 Impact factor: 2.700
Authors: Shousun C Szu; Steven Hunt; Guilin Xie; John B Robbins; Rachel Schneerson; Rajesh K Gupta; Zhigang Zhao; Xiaomei Tan Journal: Vaccine Date: 2013-02-17 Impact factor: 3.641
Authors: Mohammad Ali; Dipika Sur; Anna Lena Lopez; Suman Kanungo; R Leon Ochiai; Byomkesh Manna; Deok Ryun Kim; Jacqueline Deen; Sujit K Bhattacharya; John D Clemens Journal: J Health Popul Nutr Date: 2010-10 Impact factor: 2.000
Authors: R Leon Ochiai; Camilo J Acosta; M Carolina Danovaro-Holliday; Dong Baiqing; Sujit K Bhattacharya; Magdarina D Agtini; Zulfiqar A Bhutta; Do Gia Canh; Mohammad Ali; Seonghye Shin; John Wain; Anne-Laure Page; M John Albert; Jeremy Farrar; Remon Abu-Elyazeed; Tikki Pang; Claudia M Galindo; Lorenz von Seidlein; John D Clemens Journal: Bull World Health Organ Date: 2008-04 Impact factor: 9.408
Authors: John A Crump; Fouad G Youssef; Stephen P Luby; Momtaz O Wasfy; Josefa M Rangel; Maha Taalat; Said A Oun; Frank J Mahoney Journal: Emerg Infect Dis Date: 2003-05 Impact factor: 6.883